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Abstract
Background and Aims: Prognosis after liver transplantation differs between hepatocellular 
carcinoma (HCC) arising in cirrhotic and non-cirrhotic livers and aetiology is poorly under-
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stood. The aim was to investigate differences in mortality after liver transplantation between 
these patients. Methods: We included patients from the European Liver Transplant Registry 
transplanted due to HCC from 1990 to November 2016 and compared cirrhotic and non-cir-
rhotic patients using propensity score (PS) calibration of Cox regression estimates to adjust 
for unmeasured confounding. Results: We included 22,787 patients, of whom 96.5% had cir-
rhosis. In the unadjusted analysis, non-cirrhotic patients had an increased risk of overall mor-
tality with a hazard ratio (HR) of 1.37 (95% confidence interval [CI] 1.23–1.52). However, the HR 
approached unity with increasing adjustment and was 1.11 (95% CI 0.99–1.25) when adjusted 
for unmeasured confounding. Unadjusted, non-cirrhotic patients had an increased risk of 
HCC-specific mortality (HR 2.62, 95% CI 2.21–3.12). After adjustment for unmeasured con-
founding, the risk remained significantly increased (HR 1.62, 95% CI 1.31–2.00). Conclusions: 
Using PS calibration, we showed that HCC in non-cirrhotic liver has similar overall mortality, 
but higher HCC-specific mortality. This may be a result of a more aggressive cancer form in 
the non-cirrhotic liver as higher mortality could not be explained by tumour characteristics or 
other prognostic variables. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Hepatocellular carcinoma (HCC) represents one of the major cancers worldwide with more 
than 700,000 cases diagnosed annually [1]. The majority of HCC (70–90%) develops as a result 
of underlying chronic liver disease, with the remaining cases arising in non-cirrhotic livers [1, 2].
In cirrhotic patients, the Milan criteria were introduced in 1996 including size and 
number of HCC tumours to select patients for transplantation [3]. However, regarding patients 
with non-cirrhotic livers, macrovascular invasion and extrahepatic spread are the only 
recommended exclusion criteria for transplantation [4]. Upon diagnosis, HCC in non-cirrhotic 
livers has been reported to be fewer in number, larger, less differentiated, and more commonly 
with vascular invasion compared with HCC in cirrhotic livers [5, 6].
Earlier studies from the European Liver Transplant Registry (ELTR) reported a 5-year 
overall survival of 49% in patients undergoing liver transplantation for non-cirrhotic HCC 
compared with 75% in patients with cirrhotic livers inside the Milan criteria [7, 8]. Whether 
this difference is purely a result of different disease stage due to less strict selection criteria 
for non-cirrhotic patients is unknown.
Regarding all surgically treated HCC, a higher recurrence rate for non-cirrhotic disease 
may reflect more advanced tumours [5, 9]. Generally, due to underlying liver disease, recur-
rence risk may persist in cirrhotic patients due to sustained generation of new primary 
tumours [6]. Conversely, the vast majority of non-cirrhotic patients with recurrence present 
within 5 years, presumably reflecting recurrence of the primary tumour [10].
Observational studies may be limited due to unmeasured confounding from incomplete 
information regarding important prognostic variables [11, 12]. By using propensity score 
(PS) calibration [13–17], data available for a subset of patients with complete information on 
all confounding variables may be used to correct for unmeasured confounding in the full 
cohort. Furthermore, in contrast to studies in resected patients, data from transplanted 
patients eliminate background liver disease in cirrhotic patients, making cirrhotic and non-
cirrhotic patients more comparable.
The hypothesis of the present study was that HCC arising in non-cirrhotic livers may be 
diagnosed later due to lack of surveillance, resulting in more advanced tumours with higher 
risk of recurrence. Thus, differences in recurrence may be related to disease stage and not 
tumour biological behaviour. Conversely, a lower overall mortality in non-cirrhotic patients 
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may be related to lack of comorbidity from the underlying liver disease. Therefore, we hypoth-
esize that overall, HCC-specific and non-HCC-specific mortality are comparable between 
patients with non-cirrhotic and cirrhotic livers when investigated in a transplant setting 
using PS calibration where differences in prognostic confounding variables, including tumour 
characteristics, can be adjusted for.
The aim of the present study was to investigate differences in overall, HCC-specific, and 
non-HCC-specific mortality for patients liver transplanted for HCC with or without cirrhosis 
using PS calibration to adjust for unmeasured confounding.
Methods
The study was reported according to the STROBE guideline [18]. A protocol was registered at Clinical-
Trials.gov (ID NCT02995096). The study was approved by the Danish Data Protection Agency (RH-2018-70, 
I-Suite number 6610).
This study is a register-based observational study with prospectively recorded data from the ELTR. The 
ELTR is a pan-European database including pretransplant and follow-up data from 172 liver transplantation 
centres. Patients are treated and followed up locally at each centre. The database comprises information on 
donor, recipient, locoregional treatments, immunosuppression, pathology from explanted liver (tumour size, 
tumour number, and vascular invasion), underlying liver disease, cirrhosis, time of death, and cause of death.
We included all patients in the ELTR undergoing liver transplantation due to HCC from 1990 to November 
2016. Patients with fibrolamellar HCC were excluded (n = 57, 0.2%). The primary exposure variable was 
cirrhosis in the explanted liver based on pretransplant evaluation. The gold standard for the diagnosis of 
cirrhosis is liver biopsy evaluated with the METAVIR score [19]. However, for some patients the diagnosis 
may have been based on pretransplant imaging with an inhomogeneous hepatic surface, an enlarged caudate 
lobe, splenomegaly, ascites or collateral veins together with elevated Child-Pugh score or Model for End-
Stage Liver Disease (MELD) score, and a clinical history of decompensated cirrhosis [20, 21]. Commonly, 
patients with cirrhosis were selected for liver transplantation based on the Milan criteria [3] or similar, 
whereas patients without cirrhosis were selected for liver transplantation primarily due to unresectability 
of the tumour without extrahepatic disease [7]. The criteria for cirrhosis and selection for transplantation 
were not dictated by the ELTR and may vary between centres. Outcomes were overall mortality, HCC-specific 
mortality (death due to HCC recurrence), and non-HCC-specific mortality (death due to other causes than 
HCC recurrence). As confounder variables, we included number of HCC tumours, year of transplantation, size 
of largest tumour, vascular invasion (micro- or macrovascular), time on waiting list, centre volume, age, sex, 
locoregional treatment before transplantation, and MELD score [8, 22].
We estimated the association between cirrhosis and mortality using a Cox regression model. We esti-
mated an unadjusted model, an age- and sex-adjusted model, and a model adjusted for variables in the large 
dataset without any missing data (age, sex, year of surgery, and size of centre). We performed PS calibration 
to adjust hazard ratios (HRs) from the model adjusted for variables in the large dataset by including addi-
tional information from a subset of the dataset with complete data on other confounding variables (time on 
waiting list, number of HCC tumours, vascular invasion, size of largest tumour, locoregional treatment before 
transplantation, and MELD score). We calculated two PS in the subset with complete information. The first 
PS was the error-prone PS (XEP), where we estimated the probability of cirrhosis conditional on confounders 
measured in the whole dataset. The second PS was the corrected PS (Xcorr), where we estimated the proba-
bility of cirrhosis conditional on all confounders measured in the subset with complete information. Both PS 
models were estimated using multivariable logistic regression. We then estimated a linear measurement 
error model by regressing the corrected PS on the error-prone PS and cirrhosis (C):
E(Xcorr | C, XEP) = λ0 + λC C + λEP XEP,
where λ0, λC, and λEP are regression estimates. From the estimated coefficient for cirrhosis and mortality from 
the whole population adjusted for the error-prone PS, we subtracted the estimated coefficient for the error-
prone PS (βX) multiplied by the ratio of the parameter for cirrhosis and the error-prone PS estimated in the 
measurement model [15, 23]:
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Table 1. Baseline patient characteristics
Main study Data source with all confounders
cirrhosis no cirrhosis cirrhosis no cirrhosis
Number of patients 21,995 792 2,425 103
Female 3,710 (17%) 249 (31%) 355 (15%) 15 (15%)
Age
Min–max, years 0–79 0–73 0–77 4–67
Mean (SD), years 56.2 (8.8) 47.5 (16.5) 55.6 (9.4) 50.4 (14.4)
Operation year
1990–1996 1,478 (7%) 197 (25%) 3 (0%) 0 (0%)
1997–2000 1,437 (7%) 69 (9%) 4 (0%) 0 (0%)
2001–2002 2,114 (10%) 66 (9%) 17 (1%) 0 (0%)
2003–2004 1,817 (8%) 60 (8%) 91 (4%) 2 (2%)
2005–2006 2,202 (10%) 53 (7%) 172 (7%) 6 (6%)
2007 1,354 (6%) 35 (5%) 172 (7%) 10 (10%)
2008 1,480 (7%) 33 (4%) 285 (12%) 9 (9%)
2009 1,506 (7%) 47 (6%) 284 (12%) 15 (15%)
2010 1,570 (7%) 49 (6%) 280 (12%) 12 (12%)
2011 1,629 (7%) 52 (7%) 291 (12%) 13 (13%)
2012 1,579 (7%) 49 (6%) 328 (14%) 18 (17%)
2013 1,570 (7%) 45 (6%) 220 (9%) 11 (11%)
2014 1,247 (6%) 21 (3%) 164 (7%) 4 (4%)
2015–2016 1,012 (5%) 16 (2%) 114 (5%) 3 (3%)
Surgeries in centre
1–10 63 (0%) 21 (3%) 12 (0%) 3 (3%)
11–25 207 (1%) 17 (2%) 53 (2%) 1 (1%)
26–50 469 (2%) 24 (3%) 52 (2%) 1 (1%)
51–100 1,468 (7%) 64 (8%) 250 (10%) 4 (4%)
101–250 10,227 (47%) 459 (58%) 1,189 (49%) 81 (79%)
>250 9,561 (43%) 207 (26%) 869 (36%) 13 (13%)
Waiting time
Min–max, days 0–4073 0–1563 0–4060 0–1544
Mean (SD), days 186.4 (264.4) 124.0 (185.1) 180.9 (299.8) 169.5 (238.1)
0–26 days 2,859 (13) 185 (23) 602 (25) 27 (26)
27–80 days 3,211 (15) 153 (19) 608 (25) 24 (23)
81–208 days 3,912 (18) 146 (18) 609 (25) 24 (23)
>208 days 4,318 (20) 103 (13) 606 (25) 28 (27)
Missing 7,695 (35) 205 (26) 0 0
Size of largest HCC tumour
Min–max, mm 1–700 4–600 2–350 9–235
Mean (SD), mm 33.6 (34.4) 48.2 (56.6) 33.8 (22.9) 35.6 (33.8)
Missing 13,109 568 0 0
MELD score
Min–max 6.4–49.6 6.4–45.6 6.4–49.6 6.4–40.4
Mean (SD) 13.0 (5.9) 12.0 (5.9) 12.3 (5.5) 11.1 (5.5)
Missing 12,545 479 0 0
Number of HCC tumours
1 3,980 (18%) 117 (15%) 1,062 (44%) 52 (50%)
2–3 3,508 (16%) 58 (7%) 932 (38%) 29 (28%)
4–5 949 (4%) 25 (3%) 240 (10%) 14 (14%)
6–9 427 (2%) 6 (1%) 105 (4%) 3 (3%)
>9 422 (2%) 14 (2%) 86 (4%) 5 (5%)
Missing 12,709 (58%) 572 (72%) 0 0
Vascular invasion
No vascular invasion 5,986 (27%) 160 (20%) 1,848 (76%) 77 (75%)
Macrovascular invasion 237 (1%) 9 (1%) 92 (4%) 2 (2%)
Microvascular invasion 1,341 (6%) 47 (6%) 485 (20%) 24 (23%)
Missing 14,431 (66%) 576 (73%) 0 0
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β*E = βE – βX λC / λEP,
where β*E was the calibrated coefficient estimate for cirrhosis and mortality. We used the %blinplus macro 
[24] to include information on parameter estimates and error-prone and corrected PS models to correct the 
estimates from the whole population. The %blinplus macro provided the adjusted HR estimates, including 
95% confidence intervals (CIs) adjusted for additional uncertainty from the estimation of the measurement 
error model in the subset data. Mortality was illustrated using Kaplan-Meier plots with 95% CIs including 
numbers at risk. The analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina, 
USA) and R version 3.5.1 (R Core Team, Vienna, Austria).
Results
We included 22,787 patients, of whom 21,995 (96.5%) had cirrhosis. Among the patients 
with cirrhotic livers, 41.2% had hepatitis C-related cirrhosis, 23.9% had alcoholic cirrhosis, 
and 14.4% had hepatitis B-related cirrhosis. Among the patients without cirrhosis, 23.4% had 
hepatitis C virus, 11.7% had hepatitis B virus, 9.4% had other hepatitis viruses, and 7% had 
hemochromatosis. The subset of patients with data on all variables included 2,528, of whom 
2,425 (95.9%) had cirrhosis. These patients were comparable to those of the whole dataset 
regarding baseline characteristics (Table 1). However, the subset patients were more likely 
to be transplanted in the later part of the period. Patient characteristics were largely compa-
rable between cirrhotic and non-cirrhotic patients except for age and locoregional treatment 
while on the waiting list. Cirrhotic patients were older and less frequently underwent locore-
gional treatment (Table 1).
Median survival was 10.7 years (5-year survival 65.5%) for cirrhotic patients and 6.8 
years (5-year survival 56.4%) for non-cirrhotic patients. In the unadjusted analysis, non-
cirrhotic patients had an increased overall mortality risk with a HR of 1.37 (95% CI 1.23–1.52). 
Overall mortality is illustrated with a Kaplan-Meier plot in Figure 1. The HR approached unity 
with increasing adjustment and lastly the CIs included 1 in the PS-calibrated model (Table 2).
In the unadjusted analysis, non-cirrhotic patients had an increased risk of HCC-specif- 
ic mortality with a HR of 2.62 (95% CI 2.21–3.12). HCC-specific mortality is illustrated in 
Main study Data source with all confounders
cirrhosis no cirrhosis cirrhosis no cirrhosis
Locoregional treatment
No treatment 1,350 (6%) 40 (5%) 836 (34%) 19 (19%)
RFA 579 (3%) 62 (8%) 321 (13%) 29 (28%)
TACE 2,028 (9%) 65 (8%) 930 (38%) 33 (32%)
Resection 152 (1%) 16 (2%) 56 (2%) 7 (7%)
Other 114 (1%) 6 (1%) 28 (1%) 5 (5%)
RFA + TACE 266 (1%) 14 (2%) 144 (6%) 3 (3%)
RFA + TACE + other 47 (0%) 2 (0%) 29 (1%) 1 (1%)
Other combinations 184 (1%) 14 (2%) 81 (3%) 6 (6%)
Missing 17,275 (79%) 573 (72%) 0
Mortality 7,375 (34%) 378 (48%) 500 (21%) 25 (25%)
HCC-specific mortality 1,448 (7%) 141 (18%) 134 (6%) 10 (10%)
Values are presented as n (%) unless indicated otherwise. HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver 
Disease; RFA, radiofrequency ablation; SD, standard deviation; TACE, transarterial chemoembolization.
Table 1 (continued)
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Figure 2. The magnitude of the HR estimate decreased with increasing adjustment. However, 
the HR remained 1.62 (95% CI 1.31–2.00) in the PS-calibrated model. There was no difference 
in HR of non-HCC-specific mortality regardless of adjustment between cirrhotic and non-
cirrhotic patients (Table 3). Non-HCC-specific mortality is illustrated in Figure 3.
As shown in Table 4, lower age, locoregional treatment, microvascular invasion, and lower 
MELD score were associated with non-cirrhosis. In addition, the number of surgeries per 
centre was different between cirrhotic and non-cirrhotic patients, but with no clear pattern.
Discussion
In this study, we showed that differences in overall mortality between cirrhotic and non-
cirrhotic patients approached unity when adjusting for unmeasured confounding in the 
PS-calibrated model. In contrast, HCC-specific mortality remained increased among non-
cirrhotic patients in the PS-calibrated model. Furthermore, we showed that patients with 
non-cirrhotic HCC were younger, had lower MELD scores and a higher risk of microvascular 
invasion, and received more locoregional treatment.
In a previous study from the ELTR, 105 patients with HCC in non-cirrhotic livers were 

















































Fig. 1. Kaplan-Meier plot illustrating overall mortality with 95% confidence intervals.
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underlying liver disease, such as histological signs of inflammation, fibrosis, or cirrhosis. 
Moreover, patients were to have negative serology testing for hepatitis B and C virus infection. 
The 5-year overall survival rate was 49% for all patients. However, it increased to 59% in 
patients without macrovascular invasion or hilar lymph node involvement regardless of 
tumour size. This is comparable to the results found in the present study and indicates poorer 
survival after transplantation for non-cirrhotic HCC compared with a 5-year overall survival 
rate of 75% for cirrhotic patients inside the Milan criteria from the ELTR [8].
In a study combining resected and transplanted patients, 138 cirrhotic and 50 non-
cirrhotic patients were compared with a mean follow-up of 39 months [5]. Vascular 
invasion, larger tumour size, advanced stage, and less differentiated tumours were more 
frequent for non-cirrhotic patients. Overall survival was similar. However, recurrence was 
more common in non-cirrhotic patients (36 vs. 18%, p = 0.008). Another study evaluated 
127 non-cirrhotic, 129 Child-Pugh A cirrhotic, and 37 Child-Pugh B cirrhotic patients 
inside the Milan criteria undergoing liver resection [9]. The 5-year overall survival was 80 
and 47% for non-cirrhotic and cirrhotic patients, respectively (p < 0.0001), whereas the 
5-year recurrence rate was 54 and 81% for non-cirrhotic and cirrhotic patients, respec-
tively (p < 0.0001). The authors speculated that recurrence in cirrhotic patients may be 




















































Fig. 2. Kaplan-Meier plot illustrating HCC-specific mortality with 95% confidence intervals. HCC, hepatocel-
lular carcinoma.
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In a study investigating genetic changes in HCC tumours with comparative genomic 
hybridization, a marked difference in genomic alterations between non-cirrhotic and cirrhotic 
HCC was found [25]. Non-cirrhotic HCC exhibited more genomic variants, in particular copy 
number gain on chromosome 8q, thus supporting a separate tumour biology for non-cirrhotic 
HCC.
The present study is the largest to date to investigate transplantation in non-cirrhotic 
patients with HCC. Moreover, the study is the first of its kind to use PS calibration to adjust 
for unmeasured confounding, which may be a major issue in database studies [11, 12]. 
Included patients were comparable with respect to background liver disease and accompa-
nying comorbidity, which strongly affects outcome. However, non-cirrhotic patients are 
generally younger and may be treated differently. Closer follow-up and more focus on recur-
rence may lead to bias in reporting of HCC-specific mortality. The present study was based on 
a pretransplant diagnosis of non-cirrhosis, which may be inaccurate. However, it represents 
the scenario on which the clinical decision to select patients for transplantation is taken. 
Furthermore, studies have indicated that immunosuppression with the mammalian target of 
rapamycin inhibitor sirolimus improved prognosis in patients transplanted for HCC [26, 27]. 
Variables regarding immunosuppression are included in the ELTR database. However, due to 





















































Fig. 3. Kaplan-Meier plot illustrating non-HCC-specific mortality with 95% confidence intervals. HCC, hepa-
tocellular carcinoma.
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could not account for the fact that some patients were treated with sirolimus. Lastly, addi-
tional confounding from variables not available in the ELTR database could not be corrected 
for. Among these, pretransplant alpha-fetoprotein is considered an important prognostic 
variable [28–30], and sarcopenia has been associated with lower survival after living donor 
liver transplantation for any indication [31, 32] and higher recurrence risk after living donor 
liver transplantation for HCC [33].
OR (95% CI) p value
Female 1.00 (0.55–1.83) 0.98
Male 1.00 (ref.)





















0–26 days 1.00 (ref.)
27–80 days 1.00 (0.54–1.85)
81–208 days 0.80 (0.43–1.49)
>208 days 0.90 (0.49–1.68)
Size of largest HCC tumour, mm 1.00 (0.99–1.01) 0.85
MELD score 0.95 (0.91–0.99) 0.01
Number of HCC tumours 1.01 (0.91–1.11) 0.91
Vascular invasion 0.08
No vascular invasion 1.00 (ref.)
Macrovascular invasion 0.77 (0.17–3.43)
Microvascular invasion 1.81 (1.07–3.06)
Locoregional treatment <0.0001
No treatment 1.00 (ref.)
RFA + TACE 2.16 (0.59–7.86)
TACE 2.99 (1.58–5.67)
RFA + TACE + other 3.74 (0.44–31.46)




CI, confidence interval; HCC, hepatocellular carcinoma; MELD, 
Model for End-Stage Liver Disease; OR, odds ratio; PS, propensity score; 
RFA, radiofrequency ablation; TACE, transarterial chemoembolization.
Table 4. Logistic regression 
model of association between 
variables included in corrected 
PS model and OR of non-cirrhotic 
HCC; data source with all 
confounders (n = 2,528)
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The implication of the present study may be more strict transplantation selection criteria 
for non-cirrhotic patients in the future. Promising new methods to include alpha-fetoprotein 
[28–30] in transplantation criteria need to be validated for non-cirrhotic patients. Positron 
emission tomography/computed tomography may be used for staging of non-cirrhotic 
patients as it provides accuracy superior to that of conventional imaging [34]. Locoregional 
treatment before transplantation may be considered standard regardless of tumour charac-
teristics. Thus, response to such treatment could be used to select patients with acceptable 
prognosis [35].
In conclusion, using a method to account for unmeasured confounding in the large ELTR 
database, this study showed that HCC in non-cirrhotic livers may represent a more aggressive 
cancer form with different tumour biology. Thus, differences in recurrence rates could not be 
explained by differences in patient and tumour characteristics registered in the ELTR 
database. However, the magnitude of the estimates decreased after adjusting for unmeasured 
confounding, indicating that HCC in non-cirrhotic patients shares risk factors with HCC in 
cirrhotic patients.
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